Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology

Julio Chavez

Moffitt Cancer Center
Associate Member/Professor

I am Associate Member at the Department of Malignant Hematology and Research Director for Cellular Immunotherapy at Moffitt Cancer Center. My focus of clinical care and research is in lymphomas, specially aggressive non Hodgkin's lymphomas. I have been principal investigator in clinical trials involving CAR-T cell therapy for various types of lymphomas, including the ones that led to FDA approval. I am also part of the CAR-T Outreeach program at Moffitt Cancer Center with the idea of increasing awareness of the this therapy